The FDA has sent warning letters to Medtronic for how it has handled complaints and flaws of its neuromodulation devices, according to a Forbes report. According to the warning letter, Medtronic failed to correct a flaw in its SynchroMed II infusion pump and properly document and investigate more than 560 complaints about the device.
Medtronic is working to resolve the complaints and implement corrective action to improve its investigative process, according to a company spokeswoman.
Medtronic is working to resolve the complaints and implement corrective action to improve its investigative process, according to a company spokeswoman.
More Articles on Devices:
TransCorp Spine Granted U.S. Patent for SpinePort MIS Access System
Wright Medical Group Announces $200M in Senior Notes
Globus Medical 2Q Sales Climb 18.6% to $96M